BioSpace News Archive

Paradigm Diagnostics, Inc. announced that Palmetto GBA, the Medicare Administrative Contractor for the Molecular Diagnostics MolDX program, has reviewed the technical dossier and broadly approved the Paradigm Cancer Diagnostic assay under the Local Coverage Determination for next-generation sequencing for solid tumors..

Adamas Pharmaceuticals, Inc. announced that the compensation committee of the company’s board of directors granted two new employees the option to purchase an aggregate of 12,000 shares of the company’s common stock, at a per share exercise price of $5.11, the closing trading price on January 8, and restricted stock units to acquire 6,000 shares of the company’s common stock.

ALPHAEON Corporation, announced that it has completed a reorganization to simplify its corporate structure. As a result of this reorganization the company has split into two business units, each of which will retain the same shareholder base that was in place prior to this split off..

Shares of the Combined Company, NeuroBo Pharmaceuticals, Began Trading on the Nasdaq Exchange Under the Symbol NRBO on December 31, 2019

Helius Medical Technologies, Inc. (NASDAQ:HSDT) (TSX:HSM) (“Helius” or the “Company”), a leading neurotech company focused on neurological wellness, today announced that it is the recipient of the Pioneer Technology Development Award for its development of the PoNS™ device.

Akcea Therapeutics, Inc. (NASDAQ: AKCA), a majority-owned affiliate of Ionis Pharmaceuticals, Inc., and Ionis Pharmaceuticals, Inc. (NASDAQ: IONS), announced today the initiation of the CARDIO-TTRansform Phase 3 cardiovascular outcomes study for AKCEA-TTR-LRx in patients with transthyretin-mediated amyloid cardiomyopathy (ATTR cardiomyopathy).

Acuity Healthcare, the country’s only Employee Owned Hospital Company and a leader in long-term acute care, today announced that Executive Vice President Rick Cassady, CPA, MBA, has been promoted to Chief Operating Officer, effective immediately.

Nevro Corp. (NYSE: NVRO), a global medical device company that is providing innovative, evidence-based solutions for the treatment of chronic pain, today announced that it will host and webcast an investor briefing at the North American Neuromodulation Society (NANS 2020) in Las Vegas, NV on Saturday, January 25, 2020, beginning at 3:00 p.m. PST

Dr. Reddy’s Laboratories Ltd. will announce results for the third quarter ended December 31, 2019 on Monday, January 27, 2020 after the Board Meeting..

Passage Bio, a genetic medicines company focused on developing transformative therapies for rare, monogenic central nervous system diseases, today announced the appointment of Sandip Kapadia to its board of directors